Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHs) represent a persuasive area of research, due to their therapeutic potential in treating anemia associated with chronic kidney disease (CKD). Synthetic approaches to HIF-PHs often focus on designing small molecules that can inhibit prolyl hydroxylase enzymes, which regulate the stability and activity of hydroxylase inhibitors. The “-dustats” are a class of small-molecule prolyl hydroxylase inhibitors, representing a significant advancement in oral therapies for anemia associated with chronic kidney disease (CKD). Anemia is a common complication of CKD, a long-term condition in which the kidneys are damaged. This review aims to provide a detailed analysis of the various synthetic approaches employed in developing dustat drugs, as documented in the literature, while highlighting the latest advancements and innovations in this evolving field.
Kunta et al. (Mon,) studied this question.